![]() |
½ÃÀ庸°í¼
»óǰÄÚµå
1324889
¼¼°èÀÇ ·Î¶óŸµò ½Ã·´ ½ÃÀå : ÇöȲ ºÐ¼® ¹× ¿¹Ãø(2022-2030³â)Loratadine Syrup Market: Current Analysis and Forecast (2022-2030) |
·Î¶óŸµò ½Ã·´(Loratadine Syrup) ½ÃÀåÀº ó¹æÀü ¾øÀÌ ±¸ÀÔÇÒ ¼ö ÀÖ°í, ¾ÈÀü¼º ÇÁ·ÎÆÄÀÏÀÌ ¾çÈ£Çϸç, Á¹À½À» À¯¹ßÇÏÁö ¾Ê´Â Á¦ÇüÀ¸·Î ´Ù¾çÇÑ ¿¬·É´ëÀÇ ¼ÒºñÀÚ°¡ ¼±È£Çϱ⠶§¹®¿¡ ¾à 2%ÀÇ ²ÙÁØÇÑ ¼ºÀå·üÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¶ÇÇÑ ¾Ë·¹¸£±â¿Í ¾Ë·¹¸£±â°¡ °Ç°¿¡ ¹ÌÄ¡´Â ¿µÇâ¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö°í µµ½ÃÈ ¹× ȯ°æÀû ¿äÀÎÀ¸·Î ÀÎÇØ ¾Ë·¹¸£°Õ ³ëÃâÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ·Î¶óŸµò ½Ã·´¿¡ ´ëÇÑ ½ÃÀå ¼ö¿äµµ Áõ°¡Çϰí ÀÖ½À´Ï´Ù.
½ÃÀåÀº ¿¬·Éº°·Î ¼ºÀοë°ú ¼Ò¾Æ¿ëÀ¸·Î ±¸ºÐµË´Ï´Ù. ¿¹Ãø ±â°£ µ¿¾È ¼Ò¾Æ Ä«Å×°í¸®´Â ´õ ³ôÀº CAGRÀ» ³ªÅ¸³À´Ï´Ù. À̰ÍÀº ÁÖ·Î ¼Ò¾Æ¿¡¼ ¾Ë·¹¸£±â¿Í ²É°¡·ç ¾Ë·¹¸£±âÀÇ À¯º´·üÀÌ ³ô°í, ¼Ò¾Æ¿¡°Ô ¾ÈÀüÇÑ ¾àÁ¦ÀÇ °ËÅä, Àå½Ã°£ ÀÛ¿ëÇü Á¦Á¦¿¡ ÀÇÇÑ °ÍÀÔ´Ï´Ù. ¿¹¸¦ µé¾î, 2021³â¿¡´Â ¹Ì±¹¿¡¼ ¾à 8,100¸¸ ¸íÀÌ °èÀý¼º ¾Ë·¹¸£±â¼º ºñ¿°(ȺÐÁõ)À¸·Î Áø´ÜµÇ¾ú½À´Ï´Ù. ÀÌ´Â ¼ºÀÎÀÇ ¾à 26%(6,700¸¸ ¸í), ¾î¸°ÀÌÀÇ ¾à 19%(1,400¸¸ ¸í)¿¡ ÇØ´çÇÕ´Ï´Ù.
ÀûÀÀÁõº°·Î º¸¸é, ½ÃÀåÀº ¾Ë·¹¸£±â¼º ºñ¿°°ú µÎµå·¯±â·Î ºÐ·ùµË´Ï´Ù. ÀÌ Áß ¾Ë·¹¸£±â¼º ºñ¿°ÀÌ 2021³â ½ÃÀå¿¡¼ Å« Á¡À¯À²À» Â÷ÁöÇϰí ÀÖ½À´Ï´Ù. ÀÌ´Â ÁÖ·Î Á¤ºÎ±â°ü¿¡ ÀÇÇÑ ÅõÀÚ¡¤ÀÚ±ÝÁ¦°øÈ°µ¿ÀÇ È°¼ºÈ¿Í ¼¼°èÀÇ ¾Ë·¹¸£±â¼º ºñ¿°ÀÇ À¯º´·üÀÌ »ó½ÂÇϰí Àֱ⠶§¹®ÀÔ´Ï´Ù. ¿¹¸¦ µé¾î, ¹Ì±¹ ±¹¸³À§»ý¿¬±¸¼Ò(NIH)¿¡ µû¸£¸é ¾à 3¾ï 3,900¸¸¸íÀÌ Ãµ½Ä, 2¾ï-2¾ï 5,000¸¸¸íÀÌ À½½Ä ¾Ë·¹¸£±â, 4¾ï¸íÀÌ ºñ¿°À» ¾Î°í ÀÖ½À´Ï´Ù.
¾à¹° À¯Çü¿¡ µû¶ó ·Î¶óŸµò ½Ã·´ ½ÃÀåÀº ºê·£µå ÀǾàǰ¹°°ú Á¦³×¸¯ ÀǾàǰÀ¸·Î ºÐ·ùµË´Ï´Ù. ¿¹Ãø ±â°£ µ¿¾È ·Î¶óŸµò ½Ã·´ÀÇ µµÀÔ·üÀÌ ³ôÀº °ÍÀº ºê·£µå Á¦Ç° Ä«Å×°í¸®ÀÔ´Ï´Ù. À̰ÍÀº ÁÖ·Î Á¦¾à ȸ»ç°¡ ¸¶ÄÉÆÃ°ú ºê·£µù¿¡ ºñ¿ëÀ» ¼ÒºñÇÏ°í ·Î¿Æ¼°¡ ³ô±â ¶§¹®ÀÔ´Ï´Ù. ¶ÇÇÑ ºê·£µå ÀǾàǰÀº ÀϹÝÀûÀ¸·Î ½ÃÀå¿¡ Ãâ½ÃµÇ´Â ù ¹øÂ° ¹öÀüÀ̸ç,ÀÌ Æ¯Á¤ ¹öÀüÀº ¼ÒºñÀÚ¿¡°Ô È¿°ú¸¦ º¸ÀåÇϱâ À§ÇØ ½ÅÁßÇÑ Å×½ºÆ®¸¦ ¹Þ¾Ò½À´Ï´Ù.
·Î¶óŸµò ½Ã·´ »ê¾÷ ½ÃÀå µµÀÔ¿¡ ´ëÇÑ ÀÌÇØ¸¦ ³ôÀ̱â À§ÇØ ½ÃÀåÀº ºÏ¹Ì(¹Ì±¹, ij³ª´Ù, ±âŸ ºÏ¹Ì), À¯·´(µ¶ÀÏ, ¿µ±¹, ÇÁ¶û½º, ½ºÆäÀÎ, ÀÌÅ»¸®¾Æ, ±âŸ À¯·´), ¾Æ½Ã¾Æ ÅÂÆò¾ç(Áß±¹, ÀϺ», Àεµ ¹× ±âŸ ¾Æ½Ã¾Æ ÅÂÆò¾ç) ¹× ±âŸ ¼¼°èÀÇ ±¹°¡¿¡¼ ¼¼°èÀÇ Á¸À縦 ±â¹ÝÀ¸·Î ºÐ¼®µË´Ï´Ù. ºÏ¹Ì´Â ¿¹Ãø ±â°£ µ¿¾È »ó´çÇÑ CAGR·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. Àα¸°¡ ¸¹°í µµ½ÃÈ¿Í »ê¾÷Ȱ¡ ÁøÇàµÇ°í Àֱ⠶§¹®¿¡ ÀÌ Áö¿ª¿¡¼´Â ¾Ë·¹¸£±â Áõ·Ê°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. APAC¿¡¼´Â ȯ°æ ¿äÀÎÀ¸·Î ÀÎÇÑ ¾Ë·¹¸£±â ºñ¿°ÀÇ À¯º´·üµµ ³ô½À´Ï´Ù. ¿¹¸¦ µé¾î, ±¹¸³ÀÇÇÐ µµ¼°ü(NLM)ÀÌ ¹ßÇ¥ÇÑ ³í¹®¿¡ µû¸£¸é 13¾ï 5,000¸¸ ¸í ÀÌ»óÀÇ Àα¸¸¦ °¡Áø Àεµ¿¡´Â ¼¼°èÀÇ Àα¸ÀÇ 20% °¡±îÀÌ °ÅÁÖÇϰí ÀÖ½À´Ï´Ù. ¸¸¼º Áúȯ Áß¿¡¼µµ ¾Ë·¹¸£±â¼º ºñ¿°(AR)°ú õ½Ä°ú °°Àº ¾Ë·¹¸£±â¼º ÁúȯÀº Áö³ ¸î ³âµ¿¾È Àεµ¿¡¼ Áõ°¡Çϰí ÀÖ´Â °Í °°½À´Ï´Ù. ÀÌ Áö¿ª¿¡¼´Â ÇöÀç ¼ºÀÎÀÇ ¾à 22%°¡ ¾Ë·¹¸£±â¼º ºñ¿°(AR)À» °æÇèÇϰí ÀÖ½À´Ï´Ù. ±× °á°ú, ·Î¶óŸµò ½Ã·´°ú °°Àº È¿°úÀûÀÎ ¾Ë·¹¸£±â ¿ÏÈÁ¦¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. Áß±¹, Àεµ, ÀϺ» µî ±¹°¡¿¡¼´Â Áß°£Ãþ Áõ°¡, ÀÇ·áºñ Áõ°¡, ÀÇ·á ÀÎÇÁ¶óÀÇ °³¼±ÀÌ ½ÃÀå ¼ºÀå¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ APAC Áö¿ªÀÇ ÀϺΠ±¹°¡¿¡¼´Â ·Î¶óŸµò ½Ã·´ÀÌ OTC ÀǾàǰÀ¸·Î ÆÇ¸ÅµÇ±â ¶§¹®¿¡ ¼ÒºñÀÚ°¡ ½±°Ô ¾òÀ» ¼ö ÀÖ½À´Ï´Ù.
Loratadine syrup is a medication used to provide relief from allergy symptoms. This is known for its non-drowsy formula, making it suitable for daytime use without causing significant sedation. It effectively alleviates symptoms like sneezing, runny nose, itching, and watery eyes associated with allergies, providing long-lasting relief. The syrup formulation offers convenience, particularly for pediatric populations or individuals who have difficulty swallowing pills, as it allows for easy administration and accurate dosing. The loratadine syrup market is experiencing steady growth and is driven by several key factors such as the increasing prevalence of allergies, such as seasonal allergies, hay fever, and allergic rhinitis, which has fueled the demand for loratadine syrup. For instance, according to an article published by a U.S. organization, 339 million are suffering from asthma, 200 to 250 million have a food allergy and 400 million have rhinitis globally.
The loratadine syrup market is expected to grow at a steady rate of around 2% owing to Its over-the-counter availability, favorable safety profile, and non-drowsy formula making it a preferred choice for consumers across different age groups. Moreover, the growing awareness about allergies and their impact on health, coupled with the urbanization and environmental factors contributing to allergen exposure, has bolstered the market demand for loratadine syrup.
Based on age, the market is segmented into adult and pediatric. The pediatric category is to witness a higher CAGR during the forecast period. This is mainly due to the high prevalence of allergies and hay fever in children, consider a safe medication for children and long-acting formulations. For instance, in 2021, around 81 million people in the U.S. were diagnosed with seasonal allergic rhinitis (hay fever). This equals around 26% (67 million) of adults and 19% (14 million) of children.
On the basis of indication, the market is categorized into allergic rhinitis and urticaria. Among these, allergic rhinitis held a significant share of the market in 2021. This is mainly due to the growing investment & funding activities by government bodies and the rising prevalence of allergic rhinitis all over the world. For instance, as per the National Institutes of Health (NIH), around 339 million are suffering from asthma, 200 to 250 million have a food allergy and 400 million have rhinitis globally.
Based on drug type, the loratadine syrup market has been classified into branded and generic. The branded category is to witness higher adoption of loratadine syrup during the forecast period. This is mainly due to the pharmaceutical companies spending on marketing & branding and their loyalty being higher. Also, brand-name pills are usually the first version of the drug on the market, and this specific version has undergone careful testing to ensure efficacy to consumers.
For a better understanding of the market adoption of the loratadine syrup industry, the market is analyzed based on its worldwide presence in the countries such as North America (U.S., Canada, Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. North America is anticipated to grow at a substantial CAGR during the forecast period. the large population, coupled with increasing urbanization and industrialization, has led to a rise in allergy cases in the region. APAC also experiences a higher prevalence of allergic rhinitis due to environmental factors. For instance, as per an article published by the National Library of Medicine (NLM), with more than 1.35 billion people, India is home to nearly 20% of the global population. Of all chronic diseases, allergic diseases such as allergic rhinitis (AR) and asthma seem to increase in India over the past few years. Approximately, 22% of adults at present experience allergic rhinitis (AR) in the region. As a result, there is an increasing demand for effective allergy relief medications like loratadine syrup. The growing middle class, rising healthcare expenditure, and improving healthcare infrastructure in countries like China, India, and Japan contribute to the market growth. Additionally, the availability of loratadine syrup as an OTC medication in several countries within the APAC region makes it easily accessible to consumers.
Some of the major players operating in the market include: Merck KGaA; Cadila Pharmaceuticals; Medico Remedies Limited; Sun Pharmaceutical Industries Ltd.; GSK plc.; Perrigo Company plc; Novartis AG; Taro Pharmaceutical Industries Ltd.; Dr. Reddy's Laboratories Ltd.; and Bayer Inc.